Cerebral Protection in TAVR: Does It Improve Cognitive Function?

Cerebral Protection in TAVR sentinelNeurological complications during transcatheter aortic valve replacement (TAVR) may be reduced with cerebral protection devices; this study was designed to explore that hypothesis.

 

The study enrolled 363 patients undergoing TAVR in 19 sites and divided them in three arms:

  • a safety arm (n = 123),
  • a device imaging arm (n = 121),
  • and a non-device imaging arm (n = 119).

 

The primary safety endpoint consisted of major adverse cardiac and cerebrovascular events at 30 days The primary efficacy endpoint was reduction in new cerebral lesion volume and in brain territories protected by the device as assessed through nuclear magnetic resonance imaging scans at 2 and 7 days. All patients underwent a cognitive assessment, and all debris captured by the device was analyzed.

 

The rate of cardiac and cerebrovascular events for those who received the device was 7.3%, which was not statistically different from that of the control group, with 9.9% (p = 0.41).

 

New lesion volume on magnetic resonance scans was 179 mm3 in the control group and 102.8 mm3 in those who received the cerebral protection device, which was not statistically significant either.

 

A post hoc multivariable analysis found that the pre-existing lesion volume and the valve type were predictors of new lesions.

 

Strokes at 30 days were 9.1% in the control arm and 5.6% in the device arm (p = 0.25).

 

Neurocognitive function was similar in control subjects and subjects who received the device; when the whole population was analyzed, a correlation between lesion volume and neurocognitive decline was found (p = 0.0022).

 

Debris found within filters in 99% of patients included thrombus, calcification, native valve tissue, artery wall, and foreign material, such as gauze.

 

Conclusion

The SENTINEL cerebral protection device designed for use during transcatheter aortic valve replacements captured debris in 99% of patients. However, it did not improve cognitive function when compared to the control group. Reduction in new lesion volume as assessed through magnetic resonance scans was not statistically significant either.

 

Original title: Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement.

Reference: Samir R. Kapadia et al. J Am Coll Cardiol 2017;69:367–77.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...